Health

Cancer and specialty drugs

Generic chemotherapy injectables and specialty oncology drugs with severe supply concentration and no therapeutic substitutes.

Why it matters · Treatment delays and rationing at cancer centers when generic injectable chemo is unavailable; directly life-threatening.

Inputs

Companies

Facilities

Source countries

How it's made

The process

01
API synthesis / upstream bioprocessing
Small molecules: multi-step organic synthesis of kinase inhibitors, platinum salts, and semi-synthesis of taxanes/camptothecins from botanical extracts. Biologics: CHO cell culture in 500–25,000 L bioreactors with single-use bag technology over 10–18 day fed-batch runs.
02
Harvest & clarification
Biologics: centrifugation + depth filtration to remove cells and cell debris. Small molecules: crystallisation, centrifugation, and drying of API.
03
Purification
Biologics: three-column chromatography platform — Protein A capture (removes ~99.9% host-cell proteins), ion exchange polishing, hydrophobic-interaction polishing; viral inactivation and 20 nm viral filtration integrated. Small molecules: recrystallisation, column chromatography.
04
Formulation & fill-finish
Drug substance concentrated/diafiltered (UFDF); formulated with stabilisers; 0.2 μm sterile-filtered and aseptically filled into Type I borosilicate vials or prefilled syringes under isolator/RABS conditions. CAR-T: formulated in CryoStor CS10 and filled into cryobags at -80°C to -196°C.
05
Quality control & regulatory release
Extensive in-process and final-product testing: potency, purity, sterility, endotoxin, aggregation, particle count. Regulatory release testing per Ph.Eur / USP. Biologics: 4–8 week release cycle.
06
Cold chain distribution
mAbs and injectable chemotherapy: 2–8°C refrigerated distribution. Lyophilised products: ambient. CAR-T autologous products: liquid-nitrogen vapor-phase (-150 to -196°C) in validated Dewar dry shippers; each shipment is a unique N=1 patient consignment.

What it's made of

The inputs

11 raw inputs feed cancer and specialty drugs. Inputs flagged with ● are critical, without them, production halts.

manufactured

●

Protein A chromatography resin (mAb)

Dependency 95%

manufactured

●

Type I borosilicate glass vials

Dependency 90%

manufactured

●

Sterile filtration membrane (0.2 μm)

Dependency 88%

pharmaceutical

●

10-Deacetylbaccatin III (10-DAB)

Dependency 80%

manufactured

Platinum group metal (pharmaceutical grade)

Dependency 75%

agricultural

●

Camptothecin (botanical extract)

Dependency 75%

chemical

Lipid nanoparticle (LNP) lipid components

Dependency 70%

Where it comes from

Country dependencies

Weighted share of upstream inputs sourced from each country.

Country	Weighted share	Inputs supplied to cancer and specialty drugs
SESweden	53%	Single-use bioreactor bags · Protein A chromatography resin (mAb)
CNChina	33%	Single-use bioreactor bags · Camptothecin (botanical extract) · Cisplatin / carboplatin API +2
INIndia	31%	Camptothecin (botanical extract) · Cisplatin / carboplatin API · 10-Deacetylbaccatin III (10-DAB)
IEIreland	30%	Sterile filtration membrane (0.2 μm)
USUnited States	22%	Single-use bioreactor bags · Camptothecin (botanical extract) · CHO cell culture media +3
DEGermany	20%	Single-use bioreactor bags · CHO cell culture media · Cisplatin / carboplatin API +2
ITItaly	12%	Camptothecin (botanical extract) · 10-Deacetylbaccatin III (10-DAB) · Type I borosilicate glass vials
FRFrance	10%	Single-use bioreactor bags · CHO cell culture media · Protein A chromatography resin (mAb) +1
GBUnited Kingdom	9%	CHO cell culture media · Protein A chromatography resin (mAb) · Sterile filtration membrane (0.2 μm)
JPJapan	9%	CHO cell culture media · Protein A chromatography resin (mAb) · Sterile filtration membrane (0.2 μm) +1

Who makes it

Supplier companies

36 companies in this supply chain, sorted by market share.

Cryoport →(CYRX)

HQ US65% share

Supplies these inputs

CAR-T cryogenic dry shipper

Business segments

Biopharma Services59% rev
Life Sciences Products (MVE Biological Solutions)41% rev

Cytiva (Danaher) →(DHR)

HQ US65% share

Life sciences tools company (Marlborough, MA; wholly-owned by Danaher Corporation since $21.4B acquisition of GE Healthcare Life Sciences in 2020) that manufactures Whatman membrane filter papers and sterile filtration products alongside its dominant chromatography resin (Capto, Sephadex, Sepharose series) and bioreactor (WAVE, XDR) platforms. Cytiva is the successor to GE Healthcare Life Sciences and Amersham Biosciences. Whatman-branded products include nitrocellulose and mixed cellulose ester membranes used in sterile filtration, diagnostics, and laboratory applications. Cytiva's role in sterile filtration is secondary to Merck KGaA and Pall — Whatman filters are more prevalent in laboratory/QC applications than primary pharmaceutical manufacturing sterilization — but Cytiva's ownership alongside Pall within Danaher creates the world's most concentrated supply position in biopharmaceutical manufacturing consumables. Danaher's combined Pall + Cytiva platform spans filtration, chromatography, bioreactors, and cell culture media — covering essentially every critical consumable step in a biologics manufacturing process.

Supplies these inputs

Single-use bioreactor bags · CHO cell culture media · Protein A chromatography resin (mAb) · Sterile filtration membrane (0.2 μm)

Replaceability

Substitutability 8% · 12 mo to replace

Business segments

Protein A Chromatography Resins (World Dominant)35% rev
Single-Use Bioreactors + Cell Culture30% rev
Filtration (Whatman + Sterile)20% rev
Laboratory Instruments + Services15% rev

Intas Pharmaceuticals / Accord Healthcare →

HQ IN55% share

Intas Pharmaceuticals (Ahmedabad Gujarat India; privately held; founded 1976 by Hasmukh Chudgar; ~$2.4B revenue est. 2022) is the world's largest manufacturer of cisplatin and carboplatin APIs and one of India's largest private pharmaceutical companies. Intas operates its international generic injectable business under the brand Accord Healthcare (UK-registered subsidiary). Intas's Ahmedabad/Sanand API manufacturing complex in Gujarat was the single most important source of cisplatin API for the US market, supplying an estimated 50-60% of US cisplatin imports from its Gujarat facilities. In November 2022, FDA investigators conducting a pre-approval inspection at Intas's Ahmedabad manufacturing facility (FEI 3003889748) discovered hundreds of trash bags filled with shredded quality-control documents — evidence of deliberate document destruction intended to conceal data integrity violations. FDA issued a Form 483 with 10 observations. The FDA subsequently issued a Warning Letter in December 2022. Intas voluntarily ceased API production at the facility. The resulting API supply gap triggered the worst US oncology drug shortage in a decade, beginning in February 2023 for cisplatin and April 2023 for carboplatin. The Intas-Accord shortage became the central case study for pharmaceutical supply chain concentration risk.

Supplies these inputs

Cisplatin / carboplatin API

Replaceability

Substitutability 35% · 12 mo to replace

Business segments

Global Generics (Accord Healthcare)47% rev
India Formulations (Branded Generics)31% rev
API and Contract Manufacturing14% rev
Biologics and Biosimilars8% rev

Thermo Fisher Scientific →(TMO)

HQ US40% share

Supplies these inputs

CHO cell culture media · Lipid nanoparticle (LNP) lipid components · Protein A chromatography resin (mAb) · Sterile filtration membrane (0.2 μm)

Business segments

Laboratory Products and Biopharma Services34% rev
Life Sciences Solutions25% rev
Analytical Instruments16% rev
Specialty Diagnostics10% rev

Merck KGaA (MilliporeSigma) →

HQ DE38% share

German science and technology company (Darmstadt; family-owned since 1668; ~€22B revenue; XETRA: MRK) whose life sciences division (MilliporeSigma in North America) is the world's largest manufacturer of pharmaceutical-grade sterile filtration membranes and filter devices. Merck KGaA's filtration product lines include Durapore (PVDF, hydrophilic, 0.22 μm and 0.45 μm) — the dominant membrane for protein and buffer sterilization — and Millipore Express PLUS/SHC/SHR (PES/modified PES) for high-flow biopharmaceutical applications. Sterilizing filter devices (Millipak, Opticap XL) complete the product platform. Merck KGaA is estimated to hold ~35-40% of the global pharmaceutical sterilizing membrane market. Manufacturing is concentrated at Cork, Ireland (primary) and Jaffrey, NH and Billerica, MA (US). The Darmstadt parent that makes Durapore sterilizing filters also produces liquid crystals for LCD displays, OLED materials, photoresists for semiconductor lithography, and specialty chemicals for cosmetics — a 350-year-old German family business operating across pharmaceutical manufacturing and consumer display technology from the same corporate parent.

Supplies these inputs

Single-use bioreactor bags · Protein A chromatography resin (mAb) · Sterile filtration membrane (0.2 μm)

Replaceability

Substitutability 10% · 18 mo to replace

Business segments

Life Science (MilliporeSigma)43% rev
Healthcare (Pharma & Oncology)32% rev
Electronics (Semiconductor Materials)25% rev

Merck KGaA Life Science (MilliporeSigma) →(MRK.DE)

HQ DE35% share

Supplies these inputs

CHO cell culture media · Lipid nanoparticle (LNP) lipid components · Protein A chromatography resin (mAb) · Sterile filtration membrane (0.2 μm)

Business segments

Life Science45% rev
Healthcare32% rev
Electronics16% rev

SCHOTT Pharma AG & Co. KGaA →(SRTX.DE)

HQ DE35% share

German pharmaceutical glass specialist (FRA: 1SXP; IPO September 2023 at ~€3.6B market cap); subsidiary of SCHOTT AG, which is wholly owned by the Carl Zeiss Foundation — a non-profit foundation structure that has owned SCHOTT since 1884. SCHOTT Pharma is the world's largest manufacturer of pharmaceutical primary packaging glass, holding an estimated 35-45% of the global pharmaceutical borosilicate glass tubing market from which vials, ampoules, and syringes are drawn. Type I borosilicate glass has been SCHOTT's core product since founder Otto Schott invented borosilicate glass composition in 1884, and SCHOTT has the longest continuous manufacturing history of any pharmaceutical glass maker. Key pharmaceutical glass vial production plants in Müllheim (Germany), Jena (Germany), Schweinfurt (Germany), and multiple international sites. Supplied hundreds of millions of vials for COVID-19 vaccine programs including BioNTech/Pfizer mRNA vaccines.

Supplies these inputs

Type I borosilicate glass vials

Replaceability

Substitutability 20% · 6 mo to replace

Business segments

Pharmaceutical Glass Tubing (Type I Borosilicate)40% rev
Formed Packaging (Vials + Syringes + Cartridges)55% rev
Specialty Containers5% rev

Thermo Fisher Scientific →(TMO)

HQ US35% share

Thermo Fisher Scientific (Waltham MA; NYSE: TMO; ~$43B revenue 2024) is the world's largest manufacturer of cell culture media through its Gibco brand — the dominant label in CHO (Chinese Hamster Ovary) cell culture media for biopharmaceutical manufacturing. Gibco CHO-S Serum-Free Medium, GlutaMAX supplement, CD CHO medium, and EX-CELL Advanced CHO media series supply the majority of global monoclonal antibody manufacturing processes. Thermo Fisher's cell culture media is manufactured primarily at its Grand Island, NY facility (acquired from Life Technologies, itself formerly GIBCO BRL), which is the single most important cell culture media manufacturing site in North America. Thermo Fisher also operates a major media production site in Paisley, Scotland (UK) that serves European biopharmaceutical manufacturing. Gibco media formulations are validated into more FDA-approved biologics manufacturing processes than any other supplier — creating regulatory lock-in equivalent to Cytiva's position in chromatography resins. The 2014 Thermo Fisher merger with Life Technologies (which itself had acquired Invitrogen in 2008 and GIBCO BRL in 2000) consolidated what were once multiple competing cell culture brands into a single dominant supplier.

Supplies these inputs

Single-use bioreactor bags · CHO cell culture media

Replaceability

Substitutability 8% · 18 mo to replace

Business segments

Life Sciences Solutions40% rev
Analytical Instruments25% rev
Laboratory Products & Services25% rev
Specialty Diagnostics10% rev

Haoshu International (Hao Shu Biotech) →

HQ CN30% share

Chinese botanical extraction and pharmaceutical API company headquartered in Guangxi province — the heart of Camptotheca acuminata cultivation territory. Haoshu is among the largest producers of camptothecin and its hydroxylated derivative 10-hydroxycamptothecin (10-OHCPT) extracted from Camptotheca acuminata bark, wood, and leaves, and is a significant irinotecan API manufacturer supplying both domestic Chinese generic pharmaceutical companies and international API buyers. Guangxi's subtropical climate and rich red-clay soils support large Camptotheca acuminata plantations; Haoshu's vertical integration from plantation to API distinguishes it from pure chemical API manufacturers. The company also produces other phytochemical APIs from Chinese medicinal plant sources.

Supplies these inputs

Camptothecin (botanical extract)

Replaceability

Substitutability 25% · 60 mo to replace

Business segments

Camptothecin API (Botanical)60% rev
CPT Derivatives & Precursors30% rev
Botanical Cultivation & Extraction10% rev

Pall Corporation (Danaher) →

HQ US30% share

US filtration technology company (Port Washington, NY; wholly-owned by Danaher Corporation since 2015 acquisition for $13.8B; Danaher NYSE: DHR; ~$20B revenue). Pall is the world's second-largest pharmaceutical sterilizing filtration manufacturer with an estimated ~30% global market share. Key sterilizing membrane products: Supor (PES — polyethersulfone) membranes for high-protein and buffer applications; Fluorodyne (PVDF) for aggressive chemical compatibility. Filter devices include Kleenpak Nova, Ultipor N66, and Palltronic AerVent vent filters. Pall serves biopharma, biotechnology, food & beverage, and industrial sectors from the same filtration platform. Primary pharma manufacturing at Pensacola, FL and Fajardo, Puerto Rico. Danaher's simultaneous ownership of Pall (filtration, 30% biopharma market) AND Cytiva (chromatography resins and bioreactors, ~40% market) gives a single US industrial conglomerate unmatched consolidated control over the biopharmaceutical manufacturing consumables supply chain — a concentration with no historical precedent in the pharmaceutical equipment sector.

Supplies these inputs

Sterile filtration membrane (0.2 μm)

Replaceability

Substitutability 12% · 24 mo to replace

Business segments

Life Sciences (Pharma, Bioprocess)50% rev
Food & Beverage Filtration20% rev
Industrial Filtration (Energy, Chemical)20% rev
Aerospace & Defense Filtration10% rev

Sartorius AG →(SRT.DE)

HQ DE28% share

German laboratory and bioprocessing equipment company (Göttingen; XETRA: SRT; ~€3.4B revenue) that manufactures Sartopore 2 (PES — polyethersulfone) and Sartopore Platinum (modified PES) sterilizing membranes — the primary European alternative to Merck/Pall membrane platforms. Sartorius holds an estimated ~15% share of the pharmaceutical sterilizing filtration market, with particular strength in European biologics manufacturing. Sartorius also makes Sartocon cassette systems for tangential flow filtration (TFF), Stedim biocontainers (single-use bags), and Biowave bioreactor systems — making it, like Danaher, a vertically integrated supplier across multiple critical biopharmaceutical manufacturing unit operations. Sartorius acquired Stedim (France) in 2007 and has organically grown its bioprocessing portfolio. Göttingen primary manufacturing; additional production in Yauco, Puerto Rico (acquired via Sartorius Stedim Biotech).

Supplies these inputs

Single-use bioreactor bags · CHO cell culture media · Sterile filtration membrane (0.2 μm)

Replaceability

Substitutability 15% · 12 mo to replace

Business segments

Sterilizing Filters (Sartopore Series)25% rev
Single-Use Bioprocessing (Stedim Biotech)35% rev
Laboratory Instruments & Balances20% rev
Bioprocessing Software & Analytics20% rev

CordenPharma →

HQ CH25% share

Swiss CDMO operating European and US API manufacturing sites; primary lipid partner for Moderna; manufactures SM-102 and full LNP lipid component portfolio including ionizable, PEGylated, phosphocholine, and plant sterols; claims largest complex lipid capacity globally

Supplies these inputs

Lipid nanoparticle (LNP) lipid components

Business segments

Lipids for LNP mRNA Drug Delivery28% rev
Therapeutic Peptide APIs (GLP-1, Oncology)25% rev
Small Molecule APIs (Carbohydrate & Fatty Acid Chemistry)22% rev
Beta-Lactam Antibiotics & HPAPIs25% rev

Merck KGaA (MilliporeSigma / SAFC Biosciences) →(MRK.DE)

HQ DE25% share

Merck KGaA (Darmstadt; family-owned since 1668; Life Science division ~$9B revenue) produces CHO cell culture media through its MilliporeSigma brand in North America and SAFC (Sigma-Aldrich Formulation & Custom manufacturing) globally. SAFC Biosciences is the custom media manufacturing arm that produces proprietary 'black box' formulations for major biopharmaceutical companies under NDA — meaning a significant fraction of industry media demand is manufactured exclusively by Merck KGaA under confidential contracts. Merck KGaA's media manufacturing sites include St. Louis, Missouri (Sigma-Aldrich legacy site) and Martillac, France (custom bioscience manufacturing). The same Merck KGaA Darmstadt organization manufactures EUV photoresists (display and semiconductor), liquid crystals for flat panels, and Fractogel chromatography resins — a German family-controlled conglomerate touching monoclonal antibody media, display materials, and semiconductor chemicals from one Hessen campus.

Supplies these inputs

CHO cell culture media

Replaceability

Substitutability 10% · 30 mo to replace

Business segments

Life Science (MilliporeSigma / SAFC)45% rev
Electronics (Liquid Crystals + Semiconductor)25% rev
Healthcare Pharma (Biopharma + Oncology)30% rev

Shanxi Fenge Pharmaceutical Co., Ltd. →

HQ CN20% share

Chinese pharmaceutical API manufacturer based in Shanxi province; significant producer of camptothecin API and related semi-synthetic intermediates. Shanxi Fenge processes camptothecin extracted from Camptotheca acuminata plant material sourced from cultivation regions (principally Guangxi, Fujian, and Jiangsu) and converts it to pharmaceutical-grade camptothecin powder used as a starting material for irinotecan and topotecan semi-synthesis. The company holds Chinese GMP certification and supplies API to Chinese generic drug manufacturers and international pharmaceutical buyers.

Supplies these inputs

Camptothecin (botanical extract)

Replaceability

Substitutability 25% · 48 mo to replace

Business segments

Camptothecin & 10-HCPT API70% rev
Semi-Synthesis CPT Derivatives20% rev
Other Pharmaceutical APIs10% rev

Stevanato Group S.p.A. →

HQ IT20% share

Italian pharmaceutical glass packaging company (NYSE: STVN since June 2021 IPO; family-owned by Stevanato family; ~€800M revenue 2023); headquartered in Piombino Dese, Veneto, Italy. Stevanato is the world's second-largest pharmaceutical glass primary packaging manufacturer and the largest independent vial converter — buying borosilicate glass tubing from SCHOTT and converting it to finished pharmaceutical vials, syringes, and cartridges. Also manufactures the vial-forming machines used in vial conversion (through subsidiary Spami). Stevanato's Piombino Dese campus is one of the highest-capacity pharmaceutical glass vial conversion sites in Europe. Major supplier to COVID-19 vaccine programs. Expanding Fishers, Indiana (US) greenfield glass/plastic hybrid plant (opening 2025) for North American market.

Supplies these inputs

Type I borosilicate glass vials

Replaceability

Substitutability 25% · 18 mo to replace

Business segments

Biopharmaceutical & Diagnostic Solutions (BDS)75% rev
Engineering (Spami / Vial-Forming Machines)15% rev
Drug Delivery Systems (DDS)10% rev

Hainan Poly Pharm Co., Ltd. →

HQ CN18% share

Chinese pharmaceutical API company (Haikou, Hainan Province; listed on Shanghai Stock Exchange; majority-owned by Poly Group — a state-linked Chinese industrial conglomerate); one of China's largest paclitaxel and docetaxel API manufacturers. Hainan Poly Pharm sources 10-DAB primarily from Taxus chinensis (Chinese yew) cultivated in Yunnan and Sichuan provinces and produces paclitaxel API via semi-synthesis for Chinese domestic oncology drug manufacturers and for export. The company benefits from China's large Taxus plantation base in southern and southwestern provinces and from Poly Group's state-connected supply chain relationships. Hainan Poly Pharm is a significant but not dominant player within China's fragmented paclitaxel API sector.

Supplies these inputs

10-Deacetylbaccatin III (10-DAB)

Replaceability

Substitutability 35% · 18 mo to replace

Business segments

Paclitaxel & Docetaxel API70% rev
Other Oncology APIs20% rev
Botanical Raw Materials10% rev

Gerresheimer AG →(GXI.DE)

HQ DE17% share

German pharmaceutical packaging company (XETRA: GXI; MDAX; ~€1.8B revenue 2023); headquartered in Düsseldorf. Gerresheimer is a major pharmaceutical glass and plastic primary packaging manufacturer serving both Type I glass vials (for injectables) and plastic pharmaceutical containers. Glass manufacturing plants include Wackersdorf (Bavaria) and Tettau (Thuringia) in Germany, plus international plants in US (Vineland NJ), India, Mexico, Czech Republic. Gerresheimer is vertically integrated — operates both primary glass tubing drawing capacity and downstream vial conversion at some sites. Listed company focused primarily on high-value pharmaceutical packaging; roughly 17-20% global pharmaceutical glass vial market share.

Supplies these inputs

Type I borosilicate glass vials

Replaceability

Substitutability 30% · 18 mo to replace

Business segments

Fujian Southeast Asia Biotechnology Co., Ltd. →

HQ CN15% share

Chinese pharmaceutical and biotechnology company (Fuzhou, Fujian Province); major paclitaxel and docetaxel API producer operating extraction and semi-synthesis facilities in Fujian Province. Sources 10-DAB from Taxus chinensis plantations in Yunnan and Fujian and converts via semi-synthesis to paclitaxel API for Chinese finished-dose oncology manufacturers and for export to Asian markets. Representative of the fragmented Chinese paclitaxel API industry where multiple mid-sized provincial manufacturers collectively hold 70-80% of global API supply.

Supplies these inputs

10-Deacetylbaccatin III (10-DAB)

Replaceability

Substitutability 35% · 18 mo to replace

Business segments

Paclitaxel & Docetaxel API75% rev
Botanical Extraction (10-DAB)20% rev
Other Oncology APIs5% rev

Where it's made

Facilities

40 facilities producing inputs that feed cancer and specialty drugs.

Cytiva HyClone Cell Culture Media Plant (Logan, UT) →

Cytiva (Danaher) · Utah · manufacturing

Cytiva (formerly GE Healthcare Life Sciences) HyClone manufacturing facility in Logan UT — primary HyClone brand cell culture media production site. Originally HyClone Laboratories Inc. (founded Logan UT 1975); acquired by Thermo Fisher 2006; transferred to GE Healthcare Life Sciences 2014 as part of an asset swap; acquired by Danaher as part of the $21.4B Cytiva acquisition in 2020. Produces HyClone CDM4CHO, HyClone ActiCHO, and other serum-free CHO media. Source: https://www.cytiva.com/solutions/cell-culture

Cytiva Muskegon →

Cytiva (Danaher) · Michigan · manufacturing

Second Protein A resin site opened explicitly to reduce single-site concentration risk at Uppsala.

Cytiva Uppsala Bioprocess Manufacturing →

Cytiva (Danaher) · Uppsala County · resin-manufacturing

World's primary Protein A affinity resin manufacturing site. Former GE Healthcare Life Sciences Uppsala campus. Produces MabSelect SuRe, MabSelect PrismA, and Capto-series chromatography resins. Also manufactures Sepharose agarose bead base, single-use bioprocess bags, and crossflow filtration systems. Uppsala concentration is the most critical single-facility chokepoint in global mAb manufacturing.

Cytiva Uppsala Bioprocess Manufacturing (Sweden) →

Cytiva (Danaher) · Uppsala · manufacturing

Cytiva's primary Uppsala, Sweden bioprocess manufacturing campus — the world's most strategically critical single-use bioreactor bag production site. Manufactures Flexsafe STR bags (20L-2,000L), ReadyToProcess WAVE bags, chromatography resins (Capto, Sephadex), and filtration membranes. The Uppsala site was the primary global chokepoint for SU bag supply during the COVID-19 vaccine surge (2020-2021). The US government invoked the Defense Production Act in 2020 to require Cytiva to prioritize delivery of SU bags to US vaccine manufacturers (Pfizer, Moderna, J&J), to the disadvantage of European vaccine programs. Source: https://www.cytiva.com/company/manufacturing

Cytiva Uppsala Manufacturing & R&D →

Cytiva (Danaher) · Uppsala, Sweden · resin_manufacturing

Primary manufacturing site for Capto and Sephadex chromatography resins. Includes 3D printing (additive manufacturing) center for bioprocess hardware. Resins shipped globally to all major insulin and biologic manufacturers.

Dr. Reddy's Laboratories Hyderabad API Facility (Oncology) →

Dr. Reddy's Laboratories · Telangana · manufacturing

Dr. Reddy's Hyderabad API manufacturing complex; FDA-inspected facility producing irinotecan hydrochloride and other oncology APIs. Converts camptothecin starting material (sourced from China) to irinotecan via semi-synthetic route (camptothecin → 10-hydroxycamptothecin → irinotecan via controlled chemical transformation steps). The Hyderabad facility supplies irinotecan API for Dr. Reddy's own generic injectable finished dose manufacturing and for third-party generic pharmaceutical clients. Dr. Reddy's is among the top-3 generic irinotecan suppliers to the U.S. hospital formulary market. Source: https://www.drreddys.com/investors/annual-reports

Evonik Hanau (LNP lipid CDMO) →

Evonik Industries AG · Hesse · manufacturing

Primary GMP lipid component manufacturing for LNP-based drug delivery; supplied BioNTech COVID mRNA vaccine lipids; US BARDA committed up to $150M for US capacity expansion.

Fresenius Kabi Wilson NC Sterile Fill-Finish Campus →

Fresenius Kabi AG · North Carolina · manufacturing

Large sterile fill-finish campus in Wilson NC; produces morphine sulfate, fentanyl citrate, and hydromorphone injectable vials for US hospital market under DEA Schedule II manufacturing quota. ISO 5 cleanroom fill-finish lines. Wilson NC is Fresenius Kabi's primary US injectable opioid manufacturing site. Received FDA Warning Letter for sterile manufacturing GMP deficiencies. Also produces IV fluids and parenteral nutrition from same campus.

Fujian Southeast Asia Biotech Paclitaxel Plant (Fuzhou) →

Fujian Southeast Asia Biotechnology Co., Ltd. · Fujian Province · manufacturing

Fujian Southeast Asia Biotechnology paclitaxel API extraction and semi-synthesis facility in Fuzhou, Fujian Province. Sources 10-DAB from Yunnan and Fujian yew plantations. Produces paclitaxel API for Chinese finished-dose oncology manufacturers and Asian export markets. Source: https://www.fjdnysh.com

Fujifilm Irvine Scientific Manufacturing Facility (Santa Ana, CA) →

Fujifilm Irvine Scientific · California · manufacturing

Fujifilm Irvine Scientific primary manufacturing facility in Santa Ana CA (Orange County) — produces IS CHO-CD cell culture media series and specialty serum-free mammalian cell culture media. Also manufactures ART (assisted reproductive technology) media for IVF clinics globally. The same facility that makes Humira's cell culture media also makes the media used in human IVF procedures. Source: https://www.irvinesci.com/about/locations

Gerresheimer Wackersdorf Glass Manufacturing →

Gerresheimer AG · Bavaria · manufacturing

Gerresheimer AG primary glass pharmaceutical packaging facility in Wackersdorf, Bavaria, Germany. Produces Type I borosilicate glass vials, ampoules, and prefillable syringes. Wackersdorf is Gerresheimer's largest European glass plant and one of Germany's major pharmaceutical glass manufacturing hubs. The Wackersdorf industrial zone was previously a proposed German nuclear reprocessing site (abandoned 1989 after protests) before being redeveloped for industrial manufacturing including Gerresheimer's pharma glass operations. Sources: Gerresheimer annual report 2023; company site map.

Guangxi Camptotheca acuminata Cultivation Zone →

Haoshu International (Hao Shu Biotech) · Guangxi · cultivation

Primary Camptotheca acuminata plantation zone centered in Guangxi Zhuang Autonomous Region, China. Guangxi's warm subtropical climate, high humidity, and red-clay soils make it the most productive region for C. acuminata cultivation globally. Trees require 3-5 years of growth before meaningful alkaloid content is achieved. Bark, wood, leaves, and seed are all harvested; bark and wood have highest camptothecin concentrations (0.3-0.5% dry weight). Haoshu International and other extraction companies source plant material from Guangxi plantations. The region also hosts C. acuminata along roadsides and in forestry plots — a semi-wild cultivation pattern common for Chinese medicinal botanicals. Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609381/

Hainan Poly Pharm API Plant (Haikou, Hainan) →

Hainan Poly Pharm Co., Ltd. · Hainan Province · manufacturing

Hainan Poly Pharm's primary API manufacturing facility in Haikou, Hainan Province; produces paclitaxel and docetaxel API via semi-synthesis from 10-DAB sourced from Taxus chinensis cultivated in Yunnan and Sichuan Province plantations. Source: https://www.polyp.com.cn

Indena S.p.A. Milan & Settala Production Sites →

Indena S.p.A. · Lombardy · manufacturing

Indena's primary extraction and purification facilities in Milan and Settala (Lombardy). EMA GMP-certified; processes plant material imported from China and other botanical sources into camptothecin, paclitaxel, silymarin, and other phytochemical APIs. Indena's Italian GMP certification is a critical differentiator — it is the primary non-Chinese GMP-certified source for camptothecin-class compounds qualified for Western pharmaceutical manufacturing. Capacity is a fraction of Chinese producers but serves as the Western world's botanical extraction bridge. Source: https://www.indena.com/manufacturing-quality/manufacturing/

Indena S.p.A. Milan Botanical API Facility →

Indena S.p.A. · Lombardy · manufacturing

Indena's Milan and Settala (Lombardy) facilities produce 10-deacetylbaccatin III (10-DAB) and paclitaxel API via semi-synthesis from European yew (Taxus baccata) needle clippings sourced from European yew plantations. Also produces docetaxel, vincristine, vinblastine, and artemisinin from botanical sources. Indena's Milan operation is the largest European botanical pharmaceutical extract manufacturing site. Source: https://www.indena.com/our-facilities/

Intas Pharmaceuticals Ahmedabad API Manufacturing Complex →

Intas Pharmaceuticals / Accord Healthcare · Gujarat · manufacturing

Intas Pharmaceuticals' primary API manufacturing complex in Ahmedabad, Gujarat (including the Sanand industrial estate satellite facility, ~30 km southwest of Ahmedabad city center). FDA FEI 3003889748. This facility was the world's single largest cisplatin API production site, supplying an estimated 50-60% of US cisplatin requirements. FDA investigators visited in November 2022 and discovered hundreds of trash bags of shredded quality-control documentation — evidence of systematic data integrity violations. FDA issued 10 observations in the Form 483 and a Warning Letter in December 2022. Intas voluntarily suspended API production. The shutdown triggered the US cisplatin shortage that began February 2023 and the carboplatin shortage that began April 2023. Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intas-pharmaceuticals-limited-667094-12222022

Intas Sanand Plant (Accord Healthcare) →

Intas Pharmaceuticals / Accord Healthcare · Gujarat · manufacturing

Supplied ~50% of US cisplatin; FDA 2022 inspection found hundreds of trash bags of shredded quality-control documents; triggered 2023 US cisplatin and carboplatin shortages.

JSR Life Sciences Tsukuba R&D and Manufacturing →

JSR Corporation · Ibaraki · resin-manufacturing

JSR Corporation's life sciences R&D and Amsphere A3 Protein A resin production facility in Tsukuba Science City, Ibaraki Prefecture. JSR's Protein A resin manufacturing capacity expanded significantly post-2020 in response to COVID-era bioprocessing demand surge. Tsukuba facility also produces JSR's semiconductor photoresist R&D materials.

Johnson Matthey Royston UK Pharmaceutical Chemicals →

Johnson Matthey Pharmaceutical Materials · Hertfordshire · lab

Johnson Matthey's Royston Hertfordshire facility produces pharmaceutical-grade specialty chemicals including controlled substance APIs under UK Medicines and Healthcare products Regulatory Agency (MHRA) authorization and INCB quota. JM Royston handles pharmaceutical precious metal and other specialty chemical manufacturing.

Luye Pharma Manufacturing Complex (Yantai, Shandong) →

Luye Pharma Group Ltd. · Shandong Province · manufacturing

Luye Pharma Group's primary manufacturing complex in Yantai, Shandong Province; vertically integrated paclitaxel API production and finished-dose injectable oncology manufacturing. Produces paclitaxel injection, nab-paclitaxel (albumin-bound), and docetaxel formulations for Chinese and international markets. Source: https://www.luye.com/en/about

Merck KGaA / SAFC Biosciences (St. Louis, MO) →

Merck KGaA (MilliporeSigma / SAFC Biosciences) · Missouri · manufacturing

Merck KGaA / MilliporeSigma / SAFC Biosciences St. Louis MO — legacy Sigma-Aldrich campus and primary North American SAFC custom and standard media manufacturing site. SAFC (Sigma-Aldrich Fine Chemicals / SAFC Biosciences) produces proprietary and custom CHO cell culture media under NDA for major biopharmaceutical companies. Sigma-Aldrich was acquired by Merck KGaA for $17B in 2015. Source: https://www.sigmaaldrich.com/US/en/applications/cell-culture-applications

Merck KGaA Molsheim Bioprocess Plant →

Merck KGaA (MilliporeSigma) · Alsace · resin-manufacturing

Merck KGaA's primary bioprocess resin manufacturing site in Molsheim, Alsace France. Produces ProSep Ultra Plus (controlled-pore glass Protein A) and Eshmuno A (synthetic polymer Protein A) resins. Also produces Fractogel ion exchange resins. Molsheim is the #2 global Protein A resin production site by volume after Cytiva Uppsala.

MilliporeSigma Membrane Manufacturing (Cork, Ireland) →

Merck KGaA (MilliporeSigma) · County Cork · manufacturing

Merck KGaA / MilliporeSigma primary global membrane manufacturing site in Cork, Ireland. This is the world's largest single facility for pharmaceutical-grade PVDF (Durapore) and PES (Millipore Express) sterilizing membranes. The Cork site serves as the primary manufacturing origin for sterilizing-grade membrane used in global biopharmaceutical manufacturing. Cork was selected for its EU regulatory environment and skilled biotech/pharma workforce. A significant disruption at Cork would affect global sterile filtration supply within weeks given limited geographic redundancy. Source: https://www.emdmillipore.com/US/en/about/manufacturing/cork

Nipro Pharma Corporation Osaka Vial Plant →

Nipro Corporation · Osaka Prefecture · manufacturing

Nipro Pharma Corporation (Nipro subsidiary) pharmaceutical glass vial production in Osaka Prefecture, Japan. Primary site for Nipro's Japanese pharmaceutical glass vial output; serves both domestic Japanese pharmaceutical market and export markets. Nipro Pharma produces Type I borosilicate vials conforming to USP and JP (Japanese Pharmacopoeia) standards. Nipro is the largest pharmaceutical glass vial manufacturer in Japan and holds dominant share of the Japanese domestic parenteral packaging market. Source: https://www.nipropharma.co.jp/english/

Pall Corporation Membrane Manufacturing (Pensacola, FL) →

Pall Corporation (Danaher) · Florida · manufacturing

Pall Corporation (Danaher) primary membrane manufacturing facility in Pensacola, FL producing Supor (PES) and Fluorodyne (PVDF) pharmaceutical-grade sterilizing membranes. Pensacola is Pall's largest US pharmaceutical filtration manufacturing site, serving the North American biopharmaceutical manufacturing customer base. The Pensacola facility is in the Gulf Coast hurricane zone — Category 3-5 hurricane risk has historically affected pharmaceutical supply chain planning for Pall customers. Ivan (2004) and Sally (2020) caused significant damage to Pensacola industrial facilities. Pall experienced documented production disruptions during major Gulf Coast storm events. Source: https://www.pall.com/en/about-pall/manufacturing-locations.html

Parker Hannifin Bioscience Filtration (Birtley, UK) →

Parker Hannifin (Bioscience Division) · County Durham · manufacturing

Parker Hannifin Bioscience Division membrane manufacturing at Birtley, County Durham, UK. The Birtley site (formerly domnick hunter filtration) produces pharmaceutical-grade PVDF and PES sterilizing membrane filters for European biopharmaceutical customers. Parker acquired domnick hunter in 2008 (£150M) to enter the pharmaceutical filtration market, gaining the Birtley manufacturing site and regulatory filings. The UK location provides Parker's European pharmaceutical customers with EU/UK GMP compliant sterilizing filter supply and extractables/leachables documentation packages necessary for regulatory submissions. Source: https://www.parker.com/en/divisions/bioscience-division.html

Pfizer McPherson KS Injectable Manufacturing (Hospira legacy) →

Pfizer Inc. (Hospira / Hospital Products) · Kansas · manufacturing

Large sterile injectable manufacturing facility in McPherson KS; Hospira legacy site producing fentanyl citrate injection, morphine sulfate injection, and hydromorphone HCl injection under DEA Schedule II quota. McPherson is one of Pfizer's largest US hospital injectable volume sites. Hospira had multiple FDA Warning Letters at McPherson prior to Pfizer acquisition; Pfizer remediated. Produces vials and prefilled syringes for hospital anesthesia and ICU use.

Phyton Biotech PCF Manufacturing Facility (Port Jervis, NY) →

Phyton Biotech LLC · New York · manufacturing

Phyton Biotech's Port Jervis, New York plant is the world's largest plant cell fermentation (PCF) facility for paclitaxel API production. Uses large-scale bioreactors culturing Taxus plant cells to produce pharmaceutical-grade paclitaxel without yew tree logging. The only major US-located paclitaxel API production site. Supplies BMS (Taxol) and Fresenius Kabi generic oncology. Source: https://www.phytonbiotech.com/our-technology

Purolite (Ecolab) Pontyclun Manufacturing →

Purolite (Ecolab Life Sciences) · Wales · resin-manufacturing

Purolite's primary Praesto Protein A resin manufacturing site in Pontyclun, Rhondda Cynon Taf, Wales. Produces Praesto AP (agarose Protein A), Praesto Jetted A50 (synthetic polymer), and Praesto AC (Protein A for continuous chromatography). Welsh facility also produces industrial ion exchange resins for Ecolab's water treatment business.

Repligen Waltham Protein A Ligand Production →

Repligen Corporation · Massachusetts · ligand-manufacturing

Repligen's primary US facility for recombinant Protein A ligand production and OPUS column manufacturing. Protein A ligand produced here is supplied to third-party resin bead manufacturers including Cytiva competitors. Repligen's acquisition of ChromaTech (Sweden) expanded its ligand production to include a European site.

← Browse all goods